Voyager Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 6, 2024

VYGR$1.83-8.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)


· · Six Months Ended ·
· · June 30,
· 2024 · 2023
Cash flow from operating activities · · · · ·
Net (loss) income	$(21,471)	$101,836
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Stock-based compensation expense	7,615	5,230
Depreciation	2,588	2,161
Impairment charge on leased facility	2,776	—
Amortization of premiums and discounts on marketable securities	(4,395)	(25)
Loss on disposal of fixed assets	286	124
Changes in operating assets and liabilities:
Accounts receivable	78,448	—
Related party collaboration receivable	1,792	(3,093)
Prepaid expenses and other current assets	(1,980)	(686)
Operating lease, right-of-use asset	2,432	957
Accounts payable	1,001	(907)
Accrued expenses	(6,550)	1,296
Operating lease liabilities	(104)	(1,385)
Deferred revenue	(35,251)	17,222
Net cash provided by operating activities	27,187	122,730
Cash flow from investing activities
Purchases of property and equipment	(3,108)	(1,719)
Purchases of marketable securities	(293,859)	(28,453)
Proceeds from sales and maturities of marketable securities	164,959	20,000
Net cash used in investing activities	(132,008)	(10,172)
Cash flow from financing activities
Proceeds from the exercise of stock options	168	1,414
Proceeds from the issuance of common stock in connection with the underwritten public offering	93,473	—
Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement	19,305	—
Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement	—	31,121
Proceeds from the purchase of common stock under ESPP	481	319
Net cash provided by financing activities	113,427	32,854
Net increase in cash, cash equivalents, and restricted cash	8,606	145,412
Cash, cash equivalents, and restricted cash, beginning of period	70,395	100,474
Cash, cash equivalents, and restricted cash, end of period	$79,001	$245,886
Supplemental disclosure of cash and non-cash activities
Capital expenditures incurred but not yet paid	$—	$52
Operating lease right-of-use asset obtained in exchange for operating lease liability	$26,751	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.